<DOC>
	<DOCNO>NCT00020124</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different way may kill tumor cell . PURPOSE : Phase I trial study effectiveness inhale doxorubicin treat patient advance solid tumor affect lung .</brief_summary>
	<brief_title>Inhaled Doxorubicin Treating Patients With Advanced Solid Tumors Affecting Lungs</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose phase II dose inhale doxorubicin patient advance solid tumor affect lung . - Determine toxicity regimen patient . - Determine pharmacokinetic profile inhale doxorubicin blood patient . - Determine relationship pharmacodynamic parameter toxic effect regimen patient . OUTLINE : This dose-escalation study . Patients receive inhale doxorubicin every 3 week 3 dos . Patients stable respond disease may receive additional dos absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos doxorubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 3 week 3 month . PROJECTED ACCRUAL : Approximately 33 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced cancer curable standard chemotherapy , radiotherapy , surgery Clinical evidence primary lung tracheal cancer OR Metastatic cancer lung Extrathoracic metastases eligible follow criterion meet : Sites stable Pulmonary site primary lifethreatening site Evidence study treatment may benefit patient Measurable evaluable disease No germ cell tumor , leukemia , lymphoma involve lung treatable systemic agent No complete atelectasis due highgrade airway obstruction PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.0 mg/dL AST ALT less 1.5 time upper limit normal Renal : Creatinine great 1.6 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : LVEF least 40 % MUGA scan echocardiogram No unstable angina , congestive heart failure , symptomatic arrhythmia Pulmonary : DLCO least 50 % predict FVC FEV1 least 50 % predict Resting oxygen saturation least 90 % Exercise oxygen saturation least 85 % Oxygen consumption great 50 % predict No prior radiation pneumonitis No asthma No radiationinduced pulmonary damage Other : No hypersensitivity doxorubicin Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study HIV negative No congenital problem ( e.g. , cleave palate ) anomalies prevent tight fit mouthseal PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No prior trastuzumab ( Herceptin ) Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover Prior doxorubicin allow LVEF least 40 % MUGA scan echocardiogram No prior mitomycin , bleomycin , nitrosoureas No concurrent systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover At least 12 month since prior radiotherapy chest No prior radiotherapy 20 % total lung volume Prior chest wall primary breast radiotherapy allow Prior radioactive iodine allow No concurrent thoracic radiotherapy Surgery : See Disease Characteristics No prior total pneumonectomy Other : No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>pulmonary carcinoid tumor</keyword>
	<keyword>lung metastasis</keyword>
</DOC>